返回 
加入收藏
氘可来昔替尼治疗中重度斑块状银屑病的快速卫生技术评估
x
请在关注微信后，向客服人员索取文件
| 篇名： | 氘可来昔替尼治疗中重度斑块状银屑病的快速卫生技术评估 |
| TITLE： | Rapid health technology assessment of deucravacitinib in the treatment of moderate-to-severe plaque psoriasis |
| 摘要： | 目的 评估氘可来昔替尼在中重度斑块状银屑病治疗中的有效性、安全性和经济性。方法通过检索PubMed、WebofScience、Embase、中国知网、万方等数据库和卫生技术评估（HTA）官方网站，收集氘可来昔替尼治疗中重度斑块状银屑病的相关HTA报告、系统评价（SR）/Meta分析和药物经济学研究，检索时限为建库起至2025年7月。通过文献筛选、数据提取及文献质量评价，对研究结果进行分析和汇总。结果最终纳入14篇文献，包括HTA报告1篇、SR/Meta分析10篇、药物经济学研究3篇。在有效性方面，与安慰剂或阿普米司特相比，氘可来昔替尼在升高银屑病皮损面积和严重程度指数50/75/90/100应答率、静态医师全面评估0/1应答率、皮肤病生活质量指数0/1应答率以及降低银屑病症状和体征日记评分方面均更具优势（P＜0.05）。在安全性方面，氘可来昔替尼耐受性良好，虽然其总不良事件发生率高于安慰剂，但与阿普米司特相比差异无统计学意义；且其严重不良事件发生率、不良事件导致停药的发生率与安慰剂比较差异均无统计学意义（P＞0.05）。在经济性方面，与阿普米司特相比，氘可来昔替尼在美国、日本和中国卫生系统视角下均具有成本-效果优势。结论氘可来昔替尼治疗中重度斑块状银屑病的有效性、安全性和经济性良好，但未来仍需开展更多真实世界研究进一步完善对其的评价。 |
| ABSTRACT： | OBJECTIVE To evaluate the efficacy， safety and cost-effectiveness of deucravacitinib in the treatment of moderate- to-severe plaque psoriasis. METHODS Rapid health technology assessment （HTA） reports， systematic reviews （SR）/meta- analyses， and pharmacoeconomic studies on deucravacitinib for the treatment of moderate-to-severe plaque psoriasis were identified by searching PubMed， Web of Science， Embase， CNKI， Wanfang data and official HTA websites. The search time frame spanned from database inception to July 2025. After literature screening， data extraction， and quality assessment， the study results were subjected to descriptive analysis and synthesis. RESULTS A total of 14 articles were finally included， consisting of 1 HTA report， 10 SR/meta-analyses， and 3 pharmacoeconomic studies. Regarding efficacy， deucravacitinib demonstrated superior efficacy to both placebo and apremilast， with significantly higher response rates for Psoriasis Area and Severity Index 50/75/90/100， Static Physician’ s Global Assessment 0/1， and Dermatology Life Quality Index 0/1， as well as greater reduction in Psoriasis Symptoms and Signs Diary Score （P＜0.05）. Regarding safety， deucravacitinib was well-tolerated. Although the overall incidence of adverse events （AEs） was higher than placebo， it was not significantly different from apremilast. Moreover， the incidence of serious AEs and the rate of discontinuation due to AEs did not differ significantly from placebo （P＞0.05）. Regarding cost-effectiveness， deucravacitinib proved to be more cost-effective than apremilast across multiple healthcare system perspectives， including those of the United States， Japan， and China. CONCLUSIONS Deucravacitinib exhibits favorable efficacy， safety， and cost-effectiveness in the treatment of moderate-to-severe plaque psoriasis. Additional real-world studies are warranted to further refine its evaluation. |
| 期刊： | 2026年第37卷第01期 |
| 作者： | 高杏；孔姝婧；刘天雅；仇欣然；韩佳 |
| AUTHORS： | GAO Xing，KONG Shujing，LIU Tianya，QIU Xinran，HAN Jia |
| 关键字： | 氘可来昔替尼；中重度斑块状银屑病；快速卫生技术评估；有效性；安全性；经济性 |
| KEYWORDS： | deucravacitinib； moderate-to-severe plaque |
| 阅读数： | 45 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
